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The current project sought to examine whether delivery of lung cancer risk projections 




Two single-blinded randomised controlled trials. 
 
Setting  
Stop Smoking Services in Liverpool (UK). 
 
Subjects  




Participants allocated to intervention groups were provided with personalised lung cancer risk 
projections, calculated using the LLP risk model. 
 
Measures  
Baseline and follow-up questionnaires explored socio-demographics, smoking behavior and 
lung cancer risk perceptions. 
 
Analysis  
Bivariate analyses identified significant differences between randomisation groups and logistic 




Lung cancer risk projections were not found to predict follow-up smoking status in the trial of 
baseline current smokers; however, they did predict follow-up smoking status in the trial of 
baseline recent former smokers (OR 1.91, 95% CI 1.03-3.55). 
 
Conclusion  
The current study suggests that lung cancer risk projections may help maintain abstinence 
among individuals who have quit smoking, but the results did not provide evidence to suggest 
that lung cancer risk projections motivate current smokers to quit. 
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PURPOSE 
Lung cancer is the most commonly diagnosed cancer worldwide. In 2012, it was estimated that 
worldwide there were approximately 1.8 million new lung cancer cases and 1.6 million lung 
cancer mortalities.1 In the UK alone, approximately 86% of lung cancer cases have been 
attributed to tobacco smoking.2 Despite smoking cessation being identified as one of the most 
effective strategies in reducing lung cancer incidence,3 smoking cessation success remains at a 
mere 1-5% of smokers each year.4 Poor smoking cessation success rates demonstrate the need 
for new, innovative and effective tobacco control ventures. 
 
One of the most promising approaches to smoking cessation interventions for entire 
populations are tailored risk communications.5 A recent Cochrane review suggested that 
personalised risk information was associated with increased informed choice, increased 
knowledge, and more accurate risk perceptions.6 Furthermore, although relatively few studies 
have identified a causal association between generic risk communication and behaviour 
change, the importance of tailoring risk communications to the individual characteristics of 
targets has previously been emphasised.7 
 
Lung cancer risk prediction models are statistical models that estimate the probability of 
developing lung cancer within a given time period; such models consider and incorporate 
various risk factors. Lung cancer risk prediction models may offer a new opportunity for the 
delivery of tailored risk communications, as previous research has failed to explore the 
application of lung cancer risk prediction models in the context of smoking cessation. The 
Liverpool Lung Project (LLP) developed a lung cancer risk prediction model for predicting 
five-year risk, based on 579 lung cancer cases and 1,157 age and sex matched population-based 
controls.8 Various risk factors were incorporated into the model including, age, sex, smoking 
history, occupational exposure to asbestos, prior diagnosis of pneumonia, prior diagnosis of 
malignant tumour (except lung cancer), and family history of lung cancer. The model 
demonstrates good discrimination between cases and controls, with a reported area under the 
curve (AUC) of 0.71.8 Furthermore, the model has been validated within three independent 
populations (UK, Europe, and North America)9 and has been utilised to recruit high risk 
individuals into the UK Lung Cancer Screening Trial (UKLS).10 
 
The data within this article derive from two pragmatic randomised controlled trials (RCTs), 
which examined the feasibility and efficacy of providing personalised lung cancer risk 
projections to current and recent former smokers, with the intention of enhancing smoking 
cessation rates at six-month follow-up. The current project sought to achieve this objective by 
delivering lung cancer risk projections, calculated using the LLP risk model among individuals 
recruited via a local Stop Smoking Services (SSS), in North West England. SSS typically aim 
to support smokers within local communities to quit by providing a range of pharmacotherapy 
products and behavioural therapies.11 Secondarily, the effect of lung cancer risk projections on 
lung cancer risk perceptions was also explored, in order to provide further insight regarding 
the relationships between risk communication, risk perception, and smoking behavior. If lung 
cancer risk projections using lung cancer risk prediction models do predict follow-up smoking 
status, this has important implications; delivery of lung cancer risk projections could reduce 




All participants were consented via community drop-in sessions delivered by a SSS in North 
West England, between November 2013 and June 2014. The drop-in sessions enabled service 
users to attend at any point within a given time period and the number of service users attended 
sessions ranged greatly (0-30). It should be noted that the number of occasions that participants 
had attended SSS drop-in sessions previously was not reported. Participants were aged 18-60 
years and participants were excluded from the project if they had previously been diagnosed 
with lung cancer. The first trial incorporated a sample of current smokers (i.e. individuals who 
had smoked within the previous week) (n = 302), however, at six-month follow-up five 
participants were either deceased or relocated to an untraceable address, resulting in a final 
sample of 297 participants (see Figure 1). The second trial incorporated a sample of recent 
former smokers (i.e. those who had already stopped smoking and had not smoked at all in the 
7 days prior to recruitment) (n = 219), although at six-month follow-up three participants were 
either deceased or relocated to an untraceable address, resulting in a final sample of 216 
participants (see Figure 1); at baseline, the median number of days abstinent in the second trial 
(of recent former smokers) was 39.0 days (IQR = 21.0-75.0), with a minimum and maximum 
reported number of seven and 600 days abstinence, respectively (although only four 
participants reported abstinence for over one year).  
 
Design and procedure 
Ethical approval was acquired for the project via Liverpool Central National Research Ethics 
Service Committee. Participants were made aware that they could withdraw from the study at 
any time, data were anonymised, strict confidentiality guidelines were adhered to, and 
participants were aware that the results derived from the data they provided may be published 
in a scientific journal. 
 
The project entailed the implementation of two RCTs. The first RCT consisted of baseline 
current smokers and the second RCT consisted of baseline recent former smokers; the trials 
were undertaken in parallel. Although participants were designated to a trial based on smoking 
status, both trials followed the same design and procedure, which will now be described and is 
illustrated in Figure 1. 
 
Upon arriving at a community drop-in session delivered by a local SSS, service users were 
provided with a participant information sheet (PIS). Following service users’ consultations 
with a smoking cessation advisor, service users were introduced to a researcher by the smoking 
cessation advisor, in order to avoid influencing service users’ decisions to participate. Service 
users were offered the opportunity to discuss trial participation in greater detail, privately but 
still within the drop-in session locality. Service users who were happy to participate were 
requested to sign a consent form and complete a baseline questionnaire. The researcher offered 
to complete the questionnaire with all participants and pens were provided for those who 
wished to complete the questionnaire without the support of the researcher. 
 
Following completion of the baseline questionnaire, participants were stratified into one of the 
two trials, dictated by the participant’s baseline smoking status (i.e. baseline current smokers 
or baseline recent former smokers); smoking status classification is detailed later in the paper. 
Within the respective trial, participants were subsequently randomised into one of two groups: 
(1) the control group, or; (2) the intervention group. Randomisation software was utilised to 
allocate participants on a 1:1 ratio (via the URL, http://www.randomization.com/). Participants 
were blinded to randomisation group allocation; participants in both intervention and control 
arms were informed that they would receive lung cancer risk information but the nature of the 
information (i.e. generic or personalised) was not disclosed until debriefing. 
 
Participants allocated to the control groups for both trials were provided with simplistic, 
generic smoking risk communication in the form of a pamphlet. The generic pamphlet simply 
stated the association between smoking and lung cancer and highlighted that quitting smoking 
was the best thing to do to avoid many serious diseases, including lung cancer. Participants 
allocated to intervention groups for both trials were provided with the same generic pamphlet 
as above but additionally, they received the intervention (detailed later in this paper). 
 
Participants were informed that they would be contacted at six-months to ascertain outcome 
variables. Six-month follow-up questionnaires were predominantly undertaken by telephone. 
Telephone calls were attempted three times, at different times of the day, before a paper 
questionnaire was dispatched to a participant’s address with a stamped addressed envelope and 
letter, requesting completion. Follow-up responses relied upon participants’ goodwill, as no 
financial (or other) incentives were used. At six-month follow-up, participants were debriefed 
regarding randomisation blinding and study aims. Participants allocated to the control arm were 
offered the intervention upon completing the follow-up questionnaire and being debriefed 
regarding blinding.  
 
Measures 
Questionnaires were completed at baseline and at six-month follow-up. Baseline questionnaire 
measures included variables pertaining to socio-demographics, lung cancer risk factor 
exposure, smoking behavior, and lung cancer risk perceptions. Age, gender, ethnicity, marital 
status, highest educational attainment, and socio-economic status were ascertained. The 
measures for ethnicity and highest educational attainment have been previously adopted.12 The 
measure for marital status was based on the measure used as part of the LLP 8 whilst socio-
economic status was ascertained using English Index of Multiple Deprivation (IMD) ranks. 
IMD is a robust index, which uses 38 separate indicators of deprivation.13 IMD information 
was obtained using a website developed by Mimas at the University of Manchester14 and the 
output was reported as ranks within five quintiles, as described elsewhere.15 Socio-economic 
status and marital status variable levels were, however, subsequently transformed, due to some 
low cell frequencies. The transformed variable for socio-economic status consisted of: (1) Most 
deprived (Most deprived), and; (2) Least deprived (Above average deprivation, Average 
deprivation, Below average deprivation, Least deprived). The transformed variable for marital 
status consisted of: (1) Other (Divorced, Separated, Widowed and Other); (2) Single (Single), 
and; (3) Married or living together (Married, Living together). 
 
Data were also collected pertaining to additional lung cancer risk factor exposure, as guided by 
the LLP risk model;8 details regarding occupational exposure to asbestos, prior diagnosis of 
pneumonia, prior diagnosis of malignant tumour (except lung cancer), and family history of 
lung cancer were all established as part of the baseline questionnaire. Although these four 
variables were not of relevance to trial data analyses, they were required to calculate lung 
cancer risk projections. 
 
Smoking behavior was also investigated. Smoking status was measured at baseline using 7-day 
point prevalence (PP). 7-day PP is commonly used in smoking cessation trials and can be 
advantageous, as it captures the dynamic, real-life process of smoking cessation.16 Age started 
smoking, whether or not the participant lived with another smoker, and cigarettes per day 
(retrospectively where applicable) were recorded. Nicotine dependence was measured using 
the Fagerström Test for Nicotine Dependence (FTND).17 FTND scores were calculated based 
on six items and scores ranged from 0-10; low to high dependency. Baseline quit duration (in 
days) was also calculated among those in the second trial (i.e. baseline recent former smokers).  
 
Several lung cancer risk perceptions were additionally measured. Measures for perceived 
personal lung cancer risk, perceived lung cancer risk of the average smoker, and perceived 
relative risk of lung cancer were developed based on previously applied measures,18 whilst the 
measures for lung cancer worry and perceived lung cancer survival were adapted from a prior 
study.19  
 
The six-month follow-up questionnaire entailed several repeated measures, including smoking 
status (using 7-day PP), quit duration, and all aforementioned lung cancer risk perceptions, 
with the exception of perceived lung cancer survival, as this measure was not anticipated to be 
an outcome. Furthermore, an intention-to-treat approach was adopted at follow-up, which 
entailed classifying participants lost to follow-up as current smokers (with the exception of 
those who had died and those documented as having moved to an untraceable address).20 
 
Intervention 
The researcher delivered the intervention to participants individually, following completion of 
the baseline questionnaire. The intervention was delivered immediately after participants 
completed the baseline questionnaire and took approximately 10 minutes to deliver.  
 
The researcher brought a laptop computer to all drop-in sessions. A Microsoft Access database 
was saved on the laptop computer. The database incorporated formulae associated with the 
LLP risk model (see elsewhere) 8 and included a user interface, enabling the researcher to input 
data collected from a participant’s questionnaire to ascertain a participant’s risk profile. The 
database was able to provide an individual risk profile, using the LLP risk model formulae, by 
inputting a participant’s age, gender, smoking duration, occupational exposure to asbestos, 
prior diagnosis of pneumonia, prior diagnosis of malignant tumour (except lung cancer), and 
family history of lung cancer. The database was able to incorporate all of these risk factors and 
estimate projected five-year lung cancer risk at the age of 70 years old. 
 
Lung cancer risk at 70 years was estimated for all participants in the intervention groups and 
estimates were provided for two hypothetical circumstances: (1) continued smoking from 
present until the 70 years, and; (2) smoking cessation from present until the 70 years. Providing 
two hypothetical estimates enabled the researcher to demonstrate the benefit of stopping 
smoking, compared to continuing to smoke. For example, a 43 year old male, with 33 years 
smoking duration, a previous diagnosis of pneumonia, no previous malignancies, no family 
history of lung cancer, and no previous asbestos exposure, demonstrated a 12% projected five-
year lung cancer risk at 70 years if they continued to smoke, whereas, their projected five year 
lung cancer risk at 70 years was only 5% if the individual stopped smoking at the age of 43 
years. 
 
Lung cancer risk projections were detailed verbally to participants, including a brief 
explanation as to which risk factors informed the projections, the meaning of projected five-
year lung cancer risk at 70 years old, the projected difference between stopping and continuing 
to smoke, and a plain English summary of the LLP risk model. Participants were also offered 
the opportunity to ask questions about lung cancer risk projections. Furthermore, lung cancer 
risk projections were also presented in a pamphlet. The researcher calculated risk using the 
Microsoft Access database and discussed the resulting risk projections, with the aid of the 
pamphlet.  
 
The pamphlet stated “If you were to continue smoking, your estimated risk of getting lung 
cancer between the ages of 70 and 74 years old will be […] % BUT if you quit smoking from 
now on, your estimated risk of getting lung cancer between the ages of 70 and 74 years old will 
be reduced to […] %”. Beside each of the two estimations was an illustration that included 100 
squares. The appropriate number of squares were coloured red by the researcher to represent 
the percentage of risk for each of the estimations. The pamphlet also provided background on 
the LLP risk model, highlighted that the projections were based on the information provided 
by the participant and that if this information differed from now until the age at which risk is 
projected, the results may also differ. Lastly, the pamphlet provided contact details if the 
participant wished to find out more about the LLP risk model or the information provided. 
Participants were provided with the pamphlet to keep. 
 
Analysis 
Both trial datasets were analysed using the same analytical approach. Bivariate tests were 
undertaken to explore differences in baseline participant characteristics across randomisation 
groups. Relationships were ascertained using χ² test or Fisher’s exact test as appropriate for 
categorical variables. For continuous variables, Mann Whitney U-tests were utilised to identify 
significant differences between variable levels. Logistic regression analyses were subsequently 
conducted to explore the effect of the intervention on follow-up smoking status, perceived 
personal lung cancer risk, perceived average smoker lung cancer risk, perceived relative risk 
of lung cancer, and lung cancer worry. Purposeful selection of covariates and potential 
confounders were included as per previous guidance (i.e. the logistic regression models 
adjusted for variables significant at the level of 25%).21 All analyses were performed using 
IBM-SPSS® statistical software.22 
 
It should be noted that since there is a paucity of research regarding the provision of 
personalised lung cancer risk projections, the anticipated effect of the intervention was 
uncertain. A power calculation was undertaken to determine the required sample size for the 
trial considering baseline current smokers. The calculation indicated that a sample size 
consisting of 785 baseline current smokers (randomised on a 1:1 basis) was required to detect 
a 10% difference in smoking cessation, considering 80% power for a 5% two-sided type 1 
error, as guided by the literature.23 
 
RESULTS 
Trial 1: Baseline current smokers 
The first trial explored the intervention effect among baseline current smokers. The median age 
for the sample overall was 42.0 years old (IQR = 31.0-51.0) and most baseline current smokers 
were female (n = 177, 59.6%), White (n = 271, 92.2%), and Single (n = 157, 53.2%). 
Participants marginally tended to have higher qualifications (i.e. achieving qualifications 
beyond General Certificate of Secondary Education level) (n = 154, 53.1%), although the vast 
majority were classified within the most deprived quintile with regards to socio-economic 
status (n = 255, 86.1%). Table 1 displays the distribution of baseline participant characteristics 
across randomisation groups in respect to the first trial. 
 
A number of bivariate tests were undertaken to examine relationships between randomisation 
groups and the aforementioned baseline participant characteristics (see Table 1). Age (p = 
0.154), socio-economic status (p = 0.003), and perceived relative risk of lung cancer (p = 0.024) 
were adjusted throughout the logistic regression analyses, as these variables were significant 
at the level of 25%.21 There were no significant associations between randomisation group and 
gender, ethnicity, marital status, highest educational attainment, age started smoking, living 
with another smoker, FTND, cigarettes per day, perceived personal lung cancer risk, perceived 
average smoker lung cancer risk, lung cancer worry, and perceived lung cancer survival. 
 
Logistic regression analyses were conducted to explore the intervention effect on six-month 
follow-up outcome variables. The intervention failed to predict any of the six-month follow-
up outcome variables, including 7-day PP (smoking status) (p = 0.658), perceived personal 
lung cancer risk (p = 0.785), perceived average smoker lung cancer risk (p = 0.950), perceived 
relative risk of lung cancer (p = 0.580) and lung cancer worry (p = 0.455).  
 
Trial 2: Baseline recent former smokers 
The second trial explored the intervention effect among baseline recent former smokers. The 
median age was 44.0 years old (IQR = 37.0-52.8). The majority of baseline recent former 
smokers were female (n = 118, 54.6%) and White (n = 197, 91.6%), whilst Single was the most 
frequently reported marital status (n = 92, 43.0%). Participants marginally tended to have lower 
qualifications (i.e. achieving General Certificate of Secondary Education level or below) (n = 
114, 53.0%), and again, the vast majority were classified within the most deprived quintile in 
relation to socio-economic status (n = 182, 84.3%). 
 
Several bivariate analyses were undertaken to examine relationships between randomisation 
group and baseline participant characteristics (see Table 2). Age (p = 0.122), gender (p = 
0.243), ethnicity (p = 0.241), marital status (p = 0.178), highest educational attainment (p = 
0.001) and quit duration (p = 0.156) were adjusted throughout the logistic regression analyses, 
as these variables were significant at the level of 25%.21 There were no significant associations 
between randomisation group and socio-economic status, age started smoking, living with 
another smoker, FTND, cigarettes per day, perceived personal lung cancer risk, perceived 
average smoker lung cancer risk, perceived relative risk of lung cancer, lung cancer worry, and 
perceived lung cancer survival. 
 
Logistic regression analyses were subsequently conducted to explore the intervention effect on 
six-month follow-up outcome variables (see Table 3). The intervention was found to 
significantly predict 7-day PP (smoking status) at six months (OR 1.91 95% CI 1.03-3.55); 
however, the intervention failed to predict follow-up perceived personal lung cancer risk (p = 
0.711), perceived average smoker lung cancer risk (p = 0.567), perceived relative risk of lung 
cancer (p = 0.874) and lung cancer worry (p = 0.869). Thus, the findings suggest that lung 
cancer risk projections may promote abstinence among individuals who have recently quit 
smoking, but the results suggest they do not motivate current smokers to quit. 
 
DISCUSSION 
Previous research has suggested that tailored risk communications provide one of the most 
promising approaches to smoking cessation interventions for entire populations;5 suggesting 
that the application of lung cancer risk prediction models in the context of smoking cessation 
could prove highly beneficial in promoting smoking cessation success rates. The current study 
identified that lung cancer risk projections were associated with follow-up smoking status 
among baseline recent former smokers, but not among baseline current smokers. To our 
knowledge, this is the first study to evaluate the utility of a lung cancer risk prediction model 
in the context of smoking cessation. Our results demonstrate that the output produced from 
lung cancer risk prediction models (such as the LLP risk model8) can be adapted to deliver 
tailored lung cancer risk projections to the general public. 
 
Behavior change theory may provide some explanation as to why a significant effect was 
identified in the trial of baseline recent former smokers but not in the trial of baseline current 
smokers, as well as considering why provision of lung cancer risk projections failed to predict 
follow-up lung cancer risk perceptions in either of the trials. One of the most dominant models 
of behavior change that has been applied extensively to smoking behavior,24-26 is the 
Transtheoretical Model of Change (or TTM).27 The TTM proposes and systematically 
incorporates several concepts considered influential to behavior change, including the stages 
of change and the processes of change.27,28 Furthermore, the TTM stipulates that specific 
processes of change, such as “reinforcement management” may be more applicable among 
individuals progressing from the active stage of change to the maintenance stage of change (i.e. 
baseline recent former smokers), whereas, processes of change, such as “self-liberation” may 
be more applicable to current smokers progressing from the preparation stage of change to the 
action stage of change (i.e. baseline current smokers). This might suggest that lung cancer risk 
projections may provide recent former smokers with a reinforcing message pertaining to 
behavior change, although this message may be less applicable to current smokers preparing 
to quit smoking. Further research is required to fully understand this mechanism. 
 The study has some limitations. Firstly, it was not possible to recruit the optimal number of 
smokers in each of the trials and achievement of abstinence was substantially lower than 
anticipated for the power calculation regarding the trial of baseline current smokers (actual 
21%, compared to an expected 26%); we therefore had insufficient statistical power to 
conclude superiority of the intervention. A larger trial or extension to the current project would 
certainly be beneficial to explore whether the results are replicable. Secondly, the current 
project relied on self-reports with regards to smoking status. Future studies that explore the 
impact of tailored smoking risk communication should always endeavour to biochemically 
verify self-reported smoking status.20 Despite this, the value of self-reported smoking status 
should not be underestimated; one review surmised that sensitivity means and specificity 
means of self-reported smoking status were both high when compared with biochemical 
indices.29 
 
It should also be noted that 7-day PP was used to measure smoking status at baseline and six-
month follow-up; a measure that has been argued to be highly advantageous, enabling the 
dynamic, real-life process of smoking cessation to be captured.16 Some researchers, however, 
recommend the use of prolonged abstinence (i.e. self-reported continuous abstinence) in 
addition to point prevalence, to further enhance reliability.30 Future research might benefit from 
inclusion of both measures to improve confidence in the result that abstinence was maintained 
throughout the follow-up period. Lastly, a clustered RCT design may have also been beneficial. 
Although attempts were made to avoid contamination of randomisation blinding by delivering 
the intervention to participants in private, some participants may have inadvertently disclosed 
their randomisation group in contact with service users following the SSS drop-in session; it 
should be noted, however, that this was not apparent. 
  
In terms of behavior change theory, the current study supports the notion that stage-based 
interventions may be particularly beneficial in promoting long-term smoking cessation; a 
recent Cochrane review summarised that the effectiveness of stage-based interventions for 
smoking cessation remains unclear.26 If a future, larger trial is able to replicate the current study 
findings, a cost-benefit analysis would be beneficial to consider delivery of lung cancer risk 
projections within Stop Smoking Services on a wider scale. Stop Smoking Services quit rates 
have remained fairly constant within recent years in England;31 therefore, new, innovative and 
effective interventions would certainly be welcomed nationally and undoubtedly, 
internationally. Furthermore, lung cancer risk projections (using the LLP risk model) can be 
obtained using a simple database, thus, enabling non-clinicians to communicate lung cancer 
risk with minimal training. It may also be feasible to deliver lung cancer risk projections in 
alternate settings to local Stop Smoking Services, such as General Practitioner (GP) surgeries 
and hospital settings; however, further research is required to explore the effect of providing 
lung cancer risk projections among other smoking populations. 
 
The current study showed that provision of lung cancer risk projections predicted six-month 
follow-up smoking status among baseline recent former smokers, but not among baseline 
current smokers. The delivery of lung cancer risk projections, using risk models such as the 
LLP risk model may improve long-term smoking cessation rates, which could subsequently 
reduce the burden of smoking-related diseases and mortalities; further research is required. 
 
SO WHAT? 
What is already known on this topic? 
Smoking cessation is one of the most effective strategies in reducing lung cancer incidence and 
tailored risk communications have been identified as one of the most promising approaches to 
smoking cessation. Lung cancer risk prediction models may offer a new opportunity for the 
delivery of tailored risk communications. 
 
What does this article add? 
To our knowledge, this is the first study to explore the application of a lung cancer risk 
prediction model in the context of smoking cessation. The findings suggest that lung cancer 
risk projections may promote abstinence among individuals who have recently quit smoking, 
but they do not motivate smokers to quit. 
 
What are the implications for health promotion practice or research? 
The delivery of risk communications using lung cancer risk prediction models may greatly 
improve long-term smoking cessation rates, which may in turn reduce the burden of smoking-
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Figure 1. Flow of participants through the two project trials 
 
 
